Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.31 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9975276 | 0.90 | HPGD (0.39) | HPGDMEN1KMT2A | |
| SCHEMBL13204961 | 0.82 | KMT2A (0.35) | MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL13204866 | 0.82 | KMT2A (0.35) | MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL13205201 | 0.82 | KMT2A (0.35) | MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL6958653 | 0.82 | HPGD (0.34) | HPGDMEN1KMT2A | |
| SCHEMBL6979241 | 0.80 | TDP1 (0.36) | — | |
| SCHEMBL15865996 | 0.78 | HRH3 (0.38) | — | |
| SCHEMBL6978047 | 0.77 | SIGMAR1 (0.39) | MEN1KMT2A | |
| SCHEMBL6975379 | 0.76 | HPGD (0.33) | HPGDMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL6978377 | 0.75 | HDAC3 (0.46) | NPC1ALDH1A1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-7781469-B2 | Arylacetate derivatives having isoxazole skeleton | SHIONOGI & CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-7781469-B2 | Arylacetate derivatives having isoxazole skeleton | SHIONOGI & CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20090062531-A1 | Arylacetate Derivatives Having Isoxazole Skeleton | SHIONOGI & CO., LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090062531-A1 | Arylacetate Derivatives Having Isoxazole Skeleton | SHIONOGI & CO., LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | HPGD 3062/4885MEN1 3302/4885KMT2A 1949/4885 |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | HPGD 3062/4885MEN1 3302/4885KMT2A 1949/4885 |
| US-20090062531-A1 | Arylacetate Derivatives Having Isoxazole Skeleton | CYP2A7, CYP4X1, HAX1 | HPGD 3687/4885MEN1 3857/4885KMT2A 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.